Alzheimer's drug developer ADEL eyes December IPO

SEOUL, November 18 (AJP) - South Korean biotech firm ADEL plans to list on the KOSDAQ on Dec. 2, aiming to raise up to 54.3 billion won, the company said Wednesday. It will offer 2.17 million shares at an indicative price of 18,000 to 25,000 won per share, with retail subscriptions scheduled for Nov. 23-24.

ADEL licensed its Alzheimer's drug candidate ADEL-Y01, jointly developed with Oscotec, to French pharmaceutical giant Sanofi in a deal worth up to $1.04 billion last December, including an upfront payment of $80 million. The company plans to use its IPO proceeds to fund clinical trials, develop drug delivery technology and expand its drug pipeline.

Tags: South Korea, ADEL, KOSDAQ, IPO, Biotechnology, Alzheimer's Disease, Sanofi, Oscotec, Pharmaceuticals, Drug Development, Clinical Trials, Healthcare, Technology Licensing, Stock Market